ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New Preclinical Data

<< Previous

Bullboard Posts

Next >>

Comment by M101on Mar 29, 2023 7:28pm

61 Views

Post# 35368115

RE:New Preclinical Data

bball67 wrote: So, Promis put out a press release on March 13th saying they will present new preclinical data as part of their presentation in Europe and it would be available on the Promis website on March 28. So, I don't know why the headline of the press release would tout new preclinical data if it wasn't something important or significant. I hope it is not a dud.

Anyone here figure out what if any new preclinical data is worked into the poster?

Because if not then I must invoke the famous (and last) mocking words of Cool Hand Luke: "What we have here is a failure to communicate"

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!